- Home
- Products
- Customized ADCs
- IL12+IL23
- Anti-IL12+IL23 (Briakinumab)-MC-MMAF ADC
Anti-IL12+IL23 (Briakinumab)-MC-MMAF ADC (CAT#: ADC-W-2026)
This ADC product is comprised of an anti-IL12+IL23 monoclonal antibody conjugated via a MC linker to MMAF. The MMAF is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAF binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Name
- IL12+IL23
- Alternative Names
- IL12+IL23
- Overview
- Interleukin-12 (IL-12; one of the most important T helper 1 (Th1) cytokines) is a component of the complex signal network between lymphoid and neoplastic cells. Systemic or local administration of IL-12 upregulates vascular endothelial adhesion molecule-1 on the endothelial surface, recruits leukocytes to the tumor site, and leads to ischemic–hemorrhagic necrosis of the tumor. IL-12 also inhibits tumor angiogenesis. Interleukin-23 (IL-23) is a heterodimeric cytokine composed of an IL12B (IL-12p40) subunit (that is shared with IL12) and the IL23A (IL-23p19) subunit. A functional receptor for IL-23 (the IL-23 receptor) has been identified and is composed of IL-12R β1 and IL-23R.
- Overview
- Human Anti-IL12+IL23 IgG1-lambda antibody, Briakinumab
- Generic name
- Briakinumab
- Host animal
- Human
- Name
- MC (maleimidocaproyl)
- Description
- Noncleavable linkers, is considered noncleavable-meaning linker cleavage, and payload release does not depend on the differential properties between the plasma and some cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to occur after internalization of the ADC via antigen-mediated endocytosis and delivery to lysosomal compartment, where the antibody is degraded to the level of amino acids through intracellular proteolytic degradation.
- Name
- MMAF
- Description
- Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-HBV surface antigen (Libivirumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-1973)
- Anti-IGF1R (Figitumumab)-SPDB-DM4 ADC (CAT#: ADC-W-1257)
- Anti-IAV HA (Diridavumab(CR6261))-SMCC-DM1 ADC (CAT#: ADC-W-2066)
- Anti-TNFRSF8 (Brentuximab)-DBCO-MMAF ADC-10 (CAT#: ADC-W-262)
- Anti-KIRD2 (lirilumab)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-2082)
- Anti-TNFRSF17-PEG4-Mal-DM4 ADC-3 (CAT#: ADC-W-125)
- Anti-C. albicans Hsp90 (Efungumab)-MC-MMAF ADC (CAT#: ADC-W-2194)
- Anti-EphA2 -VC-MMAE ADC-1 (CAT#: ADC-W-398)
- Anti-IL1B (Gevokizumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-1333)
- Anti-TNFRSF17-VC-MMAE ADC-8 (CAT#: ADC-W-269)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-2026. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
Same Linker
Same Payload
| CAT# | Product Name | Linker | Payload |
| ADC-W-2025 | Anti-IL12+IL23 (Briakinumab)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
| ADC-W-1956 | Anti-IL12+IL23 (Ustekinumab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
| ADC-W-1952 | Anti-IL12+IL23 (Ustekinumab)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
| ADC-W-1957 | Anti-IL12+IL23 (Ustekinumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| ADC-W-2029 | Anti-IL12+IL23 (Briakinumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| CAT# | Product Name | Linker | Payload |
| ADC-W-478 | Anti-ENPP3-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| ADC-W-2622 | Anti-NCAM1 (Lorvotuzumab )-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-322 | Anti-CD19-Mc-MMAF ADC-1 | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| ADC-W-2606 | Anti-ITGB3 (Tadocizumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-114 | Anti-CD33-Mc-MMAF ADC-3 | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| CAT# | Product Name | Linker | Payload |
| ADC-W-2579 | Anti-CEACAM5-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2622 | Anti-NCAM1 (Lorvotuzumab )-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2612 | Anti-MS4A1 (Rituximab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2600 | Anti-GPNMB (Glembatumumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2567 | Anti-MUC16 (Sofituzumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
